NCT06568172 2026-03-18
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
14 trialsNCT07348887 2026-03-04
RTL-DART
University Health Network, Toronto
Phase NA Recruiting
NCT03493425 2026-03-02
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT04983095 2026-02-17
METRO
Umeå University
Phase NA Recruiting
NCT06650033 2026-02-05
Pelvis ART
Royal North Shore Hospital
Phase NA Recruiting
NCT06532279 2026-02-02
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT05624996 2026-01-14
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT06499870 2025-10-21
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT06549478 2025-09-17
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
City of Hope Medical Center
Phase 1 Recruiting
NCT06546267 2025-06-11
PROST-ART
IRCCS San Raffaele
Recruiting
NCT06306170 2025-04-22
GYN-ART
IRCCS San Raffaele
Recruiting
NCT06216171 2024-09-27
ProHEART
University Hospital, Essen
Phase NA Recruiting
NCT05328505 2024-09-26
MIDAS-Prostate
University Health Network, Toronto
Phase NA Recruiting